EPHX2 Antibody

What is EPHX2 and what is its biological significance?

EPHX2, also known as soluble epoxide hydrolase (sEH), acts on epoxides (alkene oxides, oxiranes) and arene oxides, playing a crucial role in xenobiotic metabolism by degrading potentially toxic epoxides. It has significant implications in multiple pathological conditions, as single nucleotide polymorphisms (SNPs) in human EPHX2 have been linked to increased risk of cardiovascular diseases, including coronary heart disease, hyperlipoproteinemia, and type-2 diabetes . Recent research has identified EPHX2 as a potential tumor suppressor in hepatocellular carcinoma (HCC) and colorectal cancer (CRC), where its downregulation correlates with disease progression and poorer prognosis .

What EPHX2 antibody types are available and how do they differ?

EPHX2 antibodies are available in several formats:

Different antibodies target distinct epitopes of EPHX2, such as amino acids 64-94 or 238-251, allowing researchers to select antibodies based on experimental requirements and species compatibility .

How do I optimize EPHX2 antibody usage for different experimental applications?

Optimizing EPHX2 antibody usage requires consideration of several parameters:

For Western Blotting:

• Start with manufacturer-recommended dilutions (1:500-1:10000, depending on antibody type)

• Use appropriate positive controls (HEK-293 cells, A549 cells, or Jurkat cells for human EPHX2)

• Verify the expected molecular weight (calculated: 63 kDa; observed: 56-63 kDa)

• Include loading controls (β-actin is commonly used)

For Immunohistochemistry:

• Choose antigen retrieval methods based on tissue type: TE buffer (pH 9.0) is recommended, with citrate buffer (pH 6.0) as an alternative

• Optimize antibody concentration through titration experiments

• Include positive tissues (e.g., human colon cancer tissue, mouse brain tissue)

• Consider automated staining platforms for consistency (e.g., Ventana Discovery Ultra)

For Immunofluorescence:

• Use cell lines with known EPHX2 expression (e.g., A549 cells, HEK-293 cells)

• Start with dilutions of 1:50-1:500 for polyclonal or 1:200-1:800 for monoclonal antibodies

• Include appropriate counterstains for subcellular localization

Each application requires individual optimization, and researchers should validate the antibody in their specific experimental system .

How should I validate the specificity of EPHX2 antibodies in my experimental system?

A comprehensive validation strategy for EPHX2 antibodies should include:

• Positive control selection:

  • Cell lines: LNCaP, A549, Jurkat, or HEK-293 cells for human studies

  • Tissues: Liver tissue (pig), brain or kidney tissue (mouse/rat)

• Negative control implementation:

  • Skeletal muscle tissue (low EPHX2 expression)

  • Antibody omission controls

  • Isotype controls matching the host species and antibody class

• Genetic manipulation approaches:

  • siRNA knockdown: Co-transfection with EPHX2-siRNA should reduce or eliminate signal

  • Overexpression systems: BacMam EPHX2-transduced cells as positive controls

  • Western blot to confirm knockdown or overexpression efficiency

• Multiple detection methods:

  • Compare results across techniques (WB, IHC, IF)

  • Use antibodies targeting different EPHX2 epitopes

  • Verify molecular weight in Western blots (56-63 kDa range)

• Cross-reactivity assessment:

  • Test across species if working with non-human models

  • Consider known species reactivity (human, mouse, rat, pig)

This systematic approach ensures reliable interpretation of experimental results with EPHX2 antibodies .

What are the optimal conditions for immunohistochemical detection of EPHX2 in tissue sections?

Successful immunohistochemical detection of EPHX2 requires optimization of several parameters:

• Tissue preparation:

  • Formalin-fixed paraffin-embedded (FFPE) sections mounted on positively charged glass slides

  • Air-dry and bake at 60°C prior to IHC

• Antigen retrieval:

  • Primary recommendation: TE buffer at pH 9.0

  • Alternative: Citrate buffer at pH 6.0

  • Heat-induced epitope retrieval using Tris-based (EDTA) buffer solution (CC1)

• Antibody selection and dilution:

  • Monoclonal antibodies: 1:2000-1:8000 dilution (e.g., mouse monoclonal clone 1A6)

  • Polyclonal antibodies: 1:50-1:500 dilution

• Detection systems:

  • Automated staining platforms (e.g., Ventana Discovery Ultra) provide consistency

  • Include appropriate positive controls (human colon cancer tissue, mouse brain tissue)

  • Include negative controls (skeletal muscle, antibody omission)

• Visualization and quantification:

  • Develop standardized scoring systems for intensity and percentage of positive cells

  • Consider digital image analysis for objective quantification

  • Use consistent imaging parameters across specimens

Following these guidelines enables reliable detection of EPHX2 in various tissues, facilitating comparative studies across different pathological conditions .

How can I design experiments to investigate EPHX2's role in cancer progression?

A comprehensive experimental design to study EPHX2's role in cancer progression should include:

• Expression profiling:

  • Compare EPHX2 expression in paired tumor and adjacent normal tissues

  • Use Western blotting and IHC with validated EPHX2 antibodies

  • Analyze public databases (TCGA, ICGC) for additional validation

• Functional studies:

  • Generate stable cell lines with EPHX2 overexpression:

    • Use lentiviral vectors as described for HCT116 cells

    • Verify expression by Western blotting with anti-EPHX2 antibodies

  • Create EPHX2 knockdown models using siRNA:

    • EPHX2-siRNA co-transfection in EPHX2-overexpressing cells

    • Include siRNA-negative control (EPHX2-OE-siRNA_NC)

• Phenotypic assays:

  • Invasion assays (EPHX2 overexpression inhibits invasion in CRC cells)

  • Apoptosis assessment (EPHX2 promotes apoptosis in cancer cells)

  • Cell proliferation and colony formation assays

• Mechanism investigation:

  • RNA-seq analysis comparing EPHX2-overexpressing cells with control cells

  • GSEA enrichment analysis with FDR <0.05 screening

  • Focus on key pathways identified: peroxisome and fatty acid degradation

• In vivo validation:

  • Xenograft models with EPHX2-modified cancer cells

  • Patient-derived xenografts with varying EPHX2 expression

  • Correlation with tumor growth, metastasis, and survival

• Clinical correlation:

  • TMA analysis of EPHX2 expression in patient cohorts

  • Correlation with clinicopathological features and survival outcomes

  • Identification of patient subgroups who may benefit from EPHX2-targeted therapies

This multifaceted approach provides comprehensive insights into EPHX2's role in cancer progression and its potential as a therapeutic target .

How can I use EPHX2 antibodies in combination with gene expression analysis?

Integrating EPHX2 antibody-based protein detection with gene expression analysis creates a powerful approach for comprehensive mechanistic studies:

• Multi-level expression analysis:

  • Protein level: Use validated EPHX2 antibodies for Western blotting and IHC

  • mRNA level: RT-qPCR for EPHX2 transcript quantification

  • Compare protein and mRNA expression to identify post-transcriptional regulation

• RNA-seq integration:

  • Perform RNA-seq on samples with varying EPHX2 expression

  • Use GSEA enrichment analysis to identify affected pathways

  • Research has identified peroxisome and fatty acid degradation pathways associated with EPHX2 function

• Pathway validation:

  • Select key genes from enriched pathways for validation using qPCR

  • Verify protein expression changes using antibodies against pathway components

  • Perform functional assays to confirm biological significance

• Systems biology approach:

  • Protein-protein interaction (PPI) analysis using String online database

  • Weighted Gene Co-expression Network Analysis (WGCNA)

  • Identify gene modules correlated with EPHX2 expression

• Data integration:

  • Correlate protein expression (from IHC/WB) with transcriptomic changes

  • Use Maximal Clique Centrality (MCC) method to calculate key proteins in PPI networks

  • Apply bioinformatic tools to identify regulatory elements affecting EPHX2 expression

This integrated approach has successfully identified EPHX2 as a core gene involved in inhibiting colorectal cancer progression through mechanisms related to metabolic reprogramming .

What statistical approaches should I use when analyzing EPHX2 expression in clinical samples?

Robust statistical analysis of EPHX2 expression in clinical samples requires a multi-faceted approach:

• Expression comparison between groups:

  • Student's t-test or Mann-Whitney U test for two-group comparisons

  • ANOVA with appropriate post-hoc tests for multiple group comparisons

  • Adjust for multiple comparisons using Bonferroni or False Discovery Rate (FDR) methods

• Survival analysis:

  • Kaplan-Meier method for survival curve generation

  • Stratify patients by EPHX2 expression levels (high vs. low)

  • Log-rank test to assess statistical significance of survival differences

  • Cox proportional hazards regression for hazard ratio (HR) calculation

  • Multivariate Cox analysis to identify independent prognostic factors

• Correlation with clinicopathological features:

  • Chi-square or Fisher's exact test for categorical variables

  • Pearson or Spearman correlation for continuous variables

  • Logistic regression to identify independent associations

  • Forest plots to visualize hazard ratios with 95% confidence intervals

• Pathway and network analysis:

  • GSEA with normalized enrichment score (NES) evaluation

  • Use FDR <0.05 for screening RNA-seq results

  • Apply stricter criteria (NES >2 and FDR <0.001) for optimal pathway identification

• Multi-cohort validation:

  • Perform analysis across independent cohorts (e.g., TCGA and ICGC)

  • Meta-analysis approaches to combine datasets

  • Assess consistency of findings across populations

How do I interpret contradictory EPHX2 expression data across different disease models?

Resolving contradictory EPHX2 expression data requires systematic analysis and contextualization:

• Disease-specific effects:

  • EPHX2 appears downregulated in certain cancers (HCC, CRC), suggesting tumor-suppressive roles

  • EPHX2 inhibition shows benefits in inflammatory conditions like inflammatory bowel disease, indicating potentially deleterious effects in these contexts

  • These seemingly contradictory findings highlight context-dependent functions

• Methodological considerations:

  • Antibody selection: Different antibodies target distinct epitopes and may yield varying results

  • Detection methods: Compare WB, IHC, and IF/ICC data

  • Quantification approaches: Standardize scoring systems across studies

• Biological explanations:

  • Tissue-specific expression patterns: EPHX2 is widely expressed across tissues with potentially different functions

  • Pathway context: EPHX2's role in fatty acid metabolism may have different implications depending on tissue metabolic requirements

  • Disease stage: Expression may change during disease progression

• Resolution strategies:

  • Perform comprehensive analysis using multiple antibodies and methods

  • Include detailed pathway analysis to contextualize findings

  • Consider post-translational modifications that may affect function without changing expression levels

  • Validate findings in multiple model systems and patient cohorts

• Functional validation:

  • Use genetic manipulation (overexpression/knockdown) to directly test functional consequences

  • Perform rescue experiments to confirm specificity

  • Consider inhibitor studies to distinguish between expression and activity effects

Understanding these context-dependent roles is critical, as illustrated by the differential effects of GSK2256294 (an EPHX2 inhibitor) in ulcerative colitis versus Crohn's disease patient samples, where it reduced different cytokine profiles in each condition .

How can EPHX2 antibodies contribute to biomarker development for cancer prognosis?

EPHX2 antibodies play a crucial role in developing prognostic biomarkers for cancer:

What methodological considerations are important when evaluating EPHX2 as a therapeutic target?

Evaluating EPHX2 as a therapeutic target requires rigorous methodological approaches:

• Context-dependent targeting strategy:

  • Disease-appropriate approach: EPHX2 inhibition for inflammatory conditions versus EPHX2 restoration for certain cancers

  • Tissue-specific considerations: EPHX2 expression varies across tissues

  • Patient stratification based on baseline EPHX2 levels

• Target validation:

  • Use multiple antibodies targeting different EPHX2 epitopes

  • Combine protein detection with functional activity assays

  • Verify both expression levels and enzymatic activity

  • Correlate with disease parameters and outcomes

• Mechanistic pathway assessment:

  • EPHX2 inhibition affects epoxyeicosatrienoic acids (EETs) with anti-inflammatory properties

  • In cancer, EPHX2 links to peroxisome and fatty acid degradation pathways

  • Pathway-specific readouts should be included in experimental design

• Model system selection:

  • Cell line models with appropriate EPHX2 expression profiles

  • Patient-derived explant cultures for ex vivo testing

  • Animal models that recapitulate human disease features

  • GSK2256294 (clinical EPHX2 inhibitor) reduced cytokine production in both ulcerative colitis and Crohn's disease patient-derived explant cultures

• Therapeutic assessment metrics:

  • For inflammatory conditions: cytokine production, inflammatory cell infiltration

  • For cancer: invasion assays, apoptosis assessment, proliferation metrics

  • In vivo endpoints: disease activity indices, survival measures

• Technological approaches:

  • AI algorithms for identifying potential EPHX2 inhibitors

  • Antibody engineering for therapeutic development

  • Personalized medicine approaches based on EPHX2 expression profiles

These methodological considerations facilitate robust evaluation of EPHX2 as a therapeutic target across different disease contexts .

How should I design research exploring EPHX2's role in metabolic reprogramming in cancer?

Investigating EPHX2's role in cancer metabolic reprogramming requires a comprehensive experimental design:

• Expression correlation with metabolic phenotypes:

  • Use validated EPHX2 antibodies for protein expression analysis

  • Correlate with metabolic enzyme expression patterns

  • Integrate with metabolomic profiling data

• Genetic manipulation strategies:

  • Establish stable cell lines with EPHX2 overexpression:

    • Lentiviral vectors for consistent expression

    • Verify using Western blotting with anti-EPHX2 antibodies (1:500-1:1000 dilution)

    • Include empty vector controls

  • Implement EPHX2 knockdown models:

    • siRNA-mediated silencing

    • CRISPR-Cas9 knockout systems

    • Confirm using antibody-based detection methods

• Metabolic pathway analysis:

  • Perform RNA-seq on EPHX2-modified cells

  • Implement GSEA enrichment analysis

  • Use strict criteria (FDR <0.05) for pathway identification

  • Focus on peroxisome and fatty acid degradation pathways identified in previous research

• Functional metabolic assays:

  • Fatty acid oxidation measurement

  • Oxygen consumption rate analysis

  • Extracellular acidification rate assessment

  • Mitochondrial function evaluation

• Mechanistic investigation:

  • Protein-protein interaction studies

  • Use maximal clique centrality (MCC) method for network analysis

  • Analyze peroxisome biogenesis and function

  • Assess lipid metabolism enzyme activity

• In vivo validation:

  • Xenograft models with EPHX2-modified cells

  • Metabolic tracer studies

  • Correlate tumor growth with metabolic parameters

  • Evaluate therapeutic interventions targeting identified pathways

This approach has successfully identified EPHX2's role in promoting fatty acid degradation as a mechanism for inhibiting colon cancer progression, providing a foundation for developing metabolism-targeted therapeutic strategies .

How can artificial intelligence enhance EPHX2-targeted drug discovery?

Artificial intelligence is revolutionizing EPHX2-targeted drug discovery through multiple innovative approaches:

• Compound screening acceleration:

  • AI algorithms identify potential EPHX2 inhibitors from existing compound libraries

  • This significantly reduces the timeline from discovery to clinical application

  • Virtual screening can evaluate millions of compounds rapidly and cost-effectively

• Structure-based drug design:

  • Machine learning models predict antibody-EPHX2 interactions

  • Optimize binding affinities for therapeutic antibodies

  • Refine small molecule inhibitor structures based on EPHX2 binding pocket analysis

• Biomarker identification:

  • AI analysis of large datasets to correlate EPHX2 expression with disease parameters

  • Identify patient subgroups likely to respond to EPHX2-targeted therapies

  • Develop algorithms integrating EPHX2 with other biomarkers for improved prediction accuracy

• Connectivity mapping approaches:

  • Computational methods compare gene expression profiles from EPHX2 inhibitor treatment with disease signatures

  • Identify inverse correlations suggesting therapeutic potential

  • This approach successfully identified EPHX2 inhibitors as potential treatments for inflammatory bowel disease

• Personalized medicine applications:

  • AI algorithms predict individual patient responses to EPHX2-targeted therapies

  • Tailor treatment regimens based on EPHX2 expression patterns

  • Optimize dosing strategies for maximum efficacy and minimal side effects

These AI-driven approaches are transforming EPHX2-targeted drug discovery, enhancing efficiency, precision, and clinical translation potential .

What are the considerations for developing novel EPHX2 antibodies for emerging research applications?

Developing next-generation EPHX2 antibodies requires consideration of several key factors:

• Epitope selection strategy:

  • Target functionally significant domains of EPHX2:

    • Hydrolase domain for enzymatic activity studies

    • Phosphatase domain for regulatory investigations

    • Protein-protein interaction regions for signaling studies

  • Design antibodies recognizing different epitopes (aa 64-94, 238-251, etc.)

• Advanced antibody engineering:

  • Phage display technology for high-affinity antibody generation

  • Hybridoma technology for monoclonal antibody development

  • Recombinant antibody approaches for consistent production

  • Site-specific modifications for enhanced performance

• Application-specific optimization:

  • Super-resolution microscopy: Bright, photostable fluorophore conjugates

  • Multiplexed IHC: Cross-reactivity minimization and specificity enhancement

  • Live-cell imaging: Membrane-permeable antibody fragments

  • Proximity-based assays: Optimized for protein-protein interaction studies

• Validation standards:

  • Comprehensive characterization across multiple techniques (WB, IHC, IF, IP)

  • Cross-validation with orthogonal detection methods

  • Genetic knockdown/knockout controls

  • Species cross-reactivity assessment (human, mouse, rat, pig)

• Production considerations:

  • Scalable manufacturing processes

  • Batch-to-batch consistency

  • Long-term stability in various storage conditions

  • Purification methods (e.g., Protein A purification for monoclonals, antigen affinity purification for polyclonals)

• Emerging applications:

  • Proximity ligation assays for protein-protein interaction studies

  • CRISPR screening validation

  • Single-cell protein analysis

  • Therapeutic antibody development

These considerations support the development of next-generation EPHX2 antibodies with enhanced specificity, consistency, and versatility for advanced research applications .

How might EPHX2 research contribute to understanding the metabolism-inflammation interface in disease?

EPHX2 research provides valuable insights into the metabolism-inflammation interface in disease pathogenesis:

• Dual functional roles:

  • Metabolic function: EPHX2 promotes fatty acid degradation and influences lipid metabolism

  • Inflammatory regulation: EPHX2 affects epoxyeicosatrienoic acids (EETs), which possess anti-inflammatory properties

• Disease-specific mechanisms:

  • Cancer: EPHX2 downregulation may promote metabolic reprogramming favoring tumor growth

  • Inflammatory bowel disease: EPHX2 inhibition reduces inflammatory cytokine production

  • Cardiovascular disease: EPHX2 polymorphisms affect lipid metabolism and inflammation

• Mechanistic investigations:

  • EPHX2 antibodies enable tissue-specific expression analysis

  • Co-localization studies with metabolic and inflammatory markers

  • Protein-protein interaction networks linking metabolic and inflammatory pathways

  • GSEA pathway analysis connecting EPHX2 to both metabolic and inflammatory processes

• Therapeutic implications:

  • Context-specific interventions targeting EPHX2:

    • Inhibition for inflammatory conditions (GSK2256294 reduced cytokine production in IBD)

    • Expression restoration for certain cancers

  • Combined approaches targeting both metabolic and inflammatory aspects of disease

• Translational research directions:

  • Biomarker development integrating metabolic and inflammatory parameters

  • Patient stratification based on EPHX2 expression and metabolic profiles

  • Precision medicine approaches tailored to specific metabolic-inflammatory phenotypes

This research highlights EPHX2's position at the metabolism-inflammation interface, offering potential for novel therapeutic strategies addressing these interconnected pathways in complex diseases .